Skip to main content
Oruka Therapeutics, Inc. logo

Oruka Therapeutics, Inc. — Investor Relations & Filings

Ticker · ORKA ISIN · US6876041087 US Manufacturing
Open in API
Filings indexed 997 across all filing types
Latest filing 2024-11-22 Capital/Financing Update
Country US United States of America
Listing US ORKA

About Oruka Therapeutics, Inc.

https://orukatx.com/

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel biologics for chronic skin diseases and other inflammatory conditions. The company applies advanced antibody engineering to validated modes of action to create potentially best-in-class monoclonal antibodies. Its lead program, ORKA-001, targets the IL-23 cytokine for the treatment of moderate-to-severe plaque psoriasis. Oruka's mission is to redefine the standard of care by developing treatments that achieve high rates of complete disease clearance with a significantly reduced dosing frequency, potentially requiring only one or two doses per year.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2024
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective time for a Registration Statement on Form S-1 filed by Oruka Therapeutics, Inc. It references the Securities Act of 1933 and Rules 460 and 461, which relate to registration statements for securities offerings. The document is a correspondence related to a capital raising process, specifically the registration of securities for an initial public offering or similar transaction. It does not contain financial statements, audit information, or detailed financial results. It is not a report but an update or request related to capital raising. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is short and it is a formal request letter, not a report or announcement of voting results or management changes.
2024-11-22 English
Regulatory Filings 2024
Regulatory Filings
2024-11-22 English
AMENDMENT NO. 2 TO SCHEDULE 13D
Major Shareholding Notification
2024-11-22 English
Director's Dealing 2024
Director's Dealing
2024-11-22 English
CURRENT REPORT
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated November 14, 2024, for Oruka Therapeutics, Inc. The key content is under Item 5.07, which details the submission of matters to a vote of security holders at a Special Meeting. It includes the voting results for two proposals: approval of conversion of Series A Preferred Stock to Common Stock and approval of an adjournment to solicit additional proxies. The document is focused on reporting the official results of shareholder votes at a meeting. There is no detailed financial data, management discussion, or audit information. The document is not a full annual or quarterly report, nor a proxy solicitation or presentation. It fits the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4650 characters, which is sufficient to contain the voting results and related details. Therefore, the correct classification is DVA with high confidence.
2024-11-18 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-11-15 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.